HF
NGNE icon

HRT Financial’s Neurogene NGNE Stock Holding History

HRT Financial’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-21,485
Closed -$321K – 3403
2025
Q2 		$321K Buy
+21,485
New +$337K ﹤0.01% 1812
2025
Q1 		– Sell
-9,933
Closed -$227K – 3102
2024
Q4 		$227K Buy
+9,933
New +$370K ﹤0.01% 1862
2021
Q4 		– Sell
-2,645
Closed -$382K – 3767
2021
Q3 		$382K Buy
+2,645
New +$405K ﹤0.01% 2243

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HRT Financial's NGNE Position: Q3 2025 in Review

HRT Financial sold out of Neurogene (NGNE) in Q3 2025, closing a stake of 21,485 shares — an estimated $321K sold.

HRT Financial first reported a position in NGNE in Q3 2021 and held it in 3 quarters. The position peaked at $382K in Q3 2021. 88 funds tracked by Wall St. Rank hold NGNE as of Q3 2025.

  • HRT Financial reported no remaining Neurogene position as of Q3 2025 after selling out during the quarter.
  • HRT Financial sold 21,485 Neurogene shares in Q3 2025, an estimated $321K.
  • HRT Financial first reported a position in Neurogene in Q3 2021 and held it in 3 quarters.
  • HRT Financial's Neurogene position peaked at $382K in Q3 2021.
  • 88 funds tracked by Wall St. Rank held Neurogene as of Q3 2025.

Based on HRT Financial's 13F filing for Q3 2025, filed 14 Nov 2025.